Panacea Venture
VC Fund
Shanghai, China
Panacea Venture is a VC fund in Shanghai focused on Biotechnology and Health Care. Panacea Venture focuses on investing and incubating R&D and innovative companies in the field of life sciences.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $257M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Panacea Venture invests in
Stages Panacea Venture invests in
Countries Panacea Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $13M–$50M
- Series A
- $1.6M–$20M
- Venture - Series Unknown
- $14M–$60M
Investment Focus
Industry
- Biotechnology 14 (61%)
- Health Care 10 (43%)
- Medical 7 (30%)
- Biopharma 5 (22%)
- Therapeutics 4 (17%)
Stage
- Series A 6 (26%)
- Seed 5 (22%)
- Venture - Series Unknown 5 (22%)
- Series B 3 (13%)
- Series C 2 (9%)
Country
- China 12 (52%)
- United States 6 (26%)
- Taiwan 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Debra Yu
Partner and COO
|
Partner and COO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $50M / Seed / Dec 31, 2024 | ||
| Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomicpowered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California. | $39.8M / Series B / Aug 21, 2024 | ||
| Eos BioInnovation is an investment firm launching and building start-ups in the area of regenerative medicine and encompasses therapies. | Seed / Jan 01, 2024 | ||
| Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stagebiopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply. | $17.4M / Series B / Feb 01, 2023 | ||
| Best Bio is a developer of cell therapy products and gene therapy products. | Series A / Jan 16, 2023 | ||
| Coastar Therapeutics develops an erythrocyte enveloped virus delivery technology platform to perform repeated virus dosing. It evades recognition and attack by the immune system to address the challenges of systemic and repeated administration of drug therapies. Coastar's process technology and “red blood cell membranes only” enable thecompany to overcome the challenges of mass production and standardization, and has cost advantages. The company's first product targets oncolytic viruses and is developing ELCV solutions for other therapies.The company was founded in 2017 and is based in San Diego, CAlifornia. | Seed / Nov 10, 2022 | ||
| Jade Biomedical provides regulatory and analytical testing services to biopharmaceutical companies worldwide. It is the world's first registered biologics contract organisation, Bio-CQOR. JADE's founder and leaders have extensive drug agency experience, including NMPA, FDA, EMA, PMDA, and PICS. Their expertise covers all therapeuticplatforms, including monoclonal antibodies, antibody-drug-conjugates, cell and gene therapies. | Series B / Sep 15, 2022 | ||
| HanchorBio is a Biotechnology Research firm that is working to revolutionize the treatment of people with cancer. | $20M / Series A / Aug 25, 2022 | ||
| FineImmu is a developer of solid tumor immunotherapy drugs, engaged in the development of solid tumor drugs and related businesses. | $13.3M / Seed / Aug 03, 2022 | ||
| GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process. | $17.5M / Series A / Mar 29, 2022 | ||
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Panacea Venture invest in?
Panacea Venture invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 23 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Panacea Venture's check size?
Panacea Venture typically joins rounds of $13M–$50M at Seed, $1.6M–$20M at Series A and $14M–$60M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Panacea Venture participates in.
How do I contact Panacea Venture?
Public channels for Panacea Venture include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Panacea Venture?
The team at Panacea Venture includes Debra Yu (Partner and COO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
